
SINT Stock Forecast & Price Target
SINT Analyst Ratings
Bulls say
SINTX Technologies is a promising biomaterials and medical device company with strong early revenue and growth in continuing operations, positioned for potential partnerships and licensing opportunities due to its unique silicon nitride material. While there are challenges including slow surgeon adoption and competition, the recent FDA clearance for their foot and ankle surgery system and partnership with Evonik are positive indicators for future success. However, risks such as low cash position and regulatory hurdles must be considered for a full assessment of the investment opportunity.
Bears say
SINTX Technologies is an advanced ceramics company with a negative outlook due to concerns about slow adoption of their silicon nitride implants, execution risk in scaling operations, dependence on partnerships for expansion, and potential competitive pressure. The company's financials, such as their Q4 2025 results, did not meet expectations and there are risks related to regulatory oversight, patent enforcement, and competition from larger orthopedic manufacturers. However, there is potential for high rewards if the company can successfully commercialize their innovative biomaterial platform, which has shown promising biological and mechanical properties, and expand into new medical applications with the use of advanced manufacturing techniques.
This aggregate rating is based on analysts' research of SINTX Technologies Inc and is not a guaranteed prediction by Public.com or investment advice.
SINT Analyst Forecast & Price Prediction
Start investing in SINT
Order type
Buy in
Order amount
Est. shares
0 shares